#	Pagina
attuale pagina	/open-h2020/projects/194704/index.html

Opendata, web and dolomites

MARKinPATH

Clinical validation of a bioMARKer for use in INtestinal PATHologies

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MARKinPATH project word cloud

Explore the words cloud of the MARKinPATH project. It provides you a very rough idea of what is the project "MARKinPATH" about.

improves meet venter massive clinical adverse regular respect pharmaceutical innovation gaxilose intellectual sme pharma expenditure lactose background suppose extensive 11 efficient sensitivity consolidation biomarker xylose adults tests innovative ing market broaden ltt specificity healthcare monitor extend breath demand pathologies health invasive paediatrics markinpath solutions population global capital commercialization tolerance diagnosis intestinal solution diseases alternative patient ingestion hbt technologies annoying hydrogen hypolactasia validation

Project "MARKinPATH" data sheet

The following table provides information about the project.

Coordinator	VENTER PHARMA S.L. Organization address address: CALLE AZALEA 1 city: ALCOBENDAS postcode: 28109 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.venterpharma.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2014
Duration (year-month-day)	from 2014-10-01 to 2015-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VENTER PHARMA S.L. VENTER PHARMA S.L. Organization address address: CALLE AZALEA 1 city: ALCOBENDAS postcode: 28109 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (ALCOBENDAS)	coordinator	50˙000.00

Map

Project objective

MARKinPATH global innovation project aims at undertake the clinical validation of Xylose, after ingestion of Gaxilose, as a Biomarker of intestinal diseases. Currently, the measurement of Xylose after ingestion of Gaxilose is used to evaluate hypolactasia in adults. MARKinPATH is focused to improve the hypolactasia diagnosis; broaden the pathologies to monitor and to extend his use to paediatrics population.

MARKinPATH will meet the demand of the EU on and innovation in healthcare, by enhancing diagnosis and management of intestinal pathologies. The resulting solution will also contribute to cost-effective and efficient health expenditure. Xylose-based, after ingestion of Gaxilose, biomarker improves technical features such as specificity and sensitivity with respect to the other tests available in regular clinical practice. Furthermore, alternative methods such as Hydrogen breath test (HBT) and the Lactose tolerance test (LTT) are invasive and have adverse effects that can be very annoying for the patient.

Venter Pharma is a highly innovative SME with more than 11 years focused on advanced research, development and commercialization of clinical solutions in this field. Venter Pharma has a relevant Intellectual Capital and an extensive background in these technologies.

MARKinPATH would suppose a massive-but-necessary growth and the consolidation of Venter Pharma in the pharmaceutical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MARKINPATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MARKINPATH" are provided by the European Opendata Portal: CORDIS opendata.